SS Innovations International Inc. (NASDAQ: SSII) CEO Dr. Sudhir Srivastava recently detailed the company's strategy to expand affordable robotic surgery access in a Medsider interview. The company focuses on reducing equipment costs and improving accessibility, with artificial intelligence, automation, and new robotic platforms central to its long-term product roadmap. Dr. Srivastava emphasized that affordability and accessibility remain core priorities as SS Innovations expands its surgical robotics platform globally.
The SSi Mantra system, designed to reduce the cost of robotic surgery, supports multiple specialties including cardiac surgery. The company has installed more than 200 robotic systems and completed over 11,700 robotic procedures, including more than 170 telesurgeries. Telesurgery and teleproctoring are becoming important differentiators, allowing expert surgeons to support complex procedures remotely. SS Innovations is pursuing FDA and European regulatory approvals while expanding into additional international markets.
Rather than solely competing with existing platforms, Dr. Srivastava described SS Innovations' objective as expanding access to hospitals and patients historically unable to adopt robotic surgery due to equipment costs and operating expenses. The company's strategy includes physician training and remote surgical capabilities to broaden adoption. For investors evaluating emerging medical technology companies, the competitive advantages behind a product can be as important as financial results.
SS Innovations is part of a portfolio of brands under IBN, which delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. More information is available at MissionIR.com and the company's newsroom at https://ibn.fm/SSII.
